April 2026 Research Update

What this month showed

This month added several real-world reports where complement-blocking medicines were used in high-stakes situations, and patients improved without new safety concerns being highlighted. Across these studies, eculizumab and ravulizumab were described as working in situations that patients often worry about most, such as childhood disease, pregnancy, and kidney transplant-related complications. The main message is not that outcomes are guaranteed, but that multiple reports described recovery or control of thrombotic microangiopathy when complement blocking was used. [1] [2] [3] [4]

In a small group of 10 children treated with eculizumab at one center, kidney-related lab measures improved quickly, and all children were dialysis-free by 4 weeks. Some families and clinicians chose to stop eculizumab after a few months, and no relapses were reported during the follow-up period described, although the follow-up was still relatively short. This adds to the picture that some children may stabilize on treatment and remain stable for a time after stopping, but it does not answer who can stop safely in general. [1]

Three single-patient reports focused on situations where aHUS or complement-mediated thrombotic microangiopathy can be especially complex: pregnancy, COVID-19 in a kidney transplant recipient, and recurrent problems around kidney transplantation. In one pregnancy case, ravulizumab was started after an aHUS relapse at 25 weeks, followed by rapid blood-count and kidney recovery and a full-term delivery without reported maternal or neonatal complications. Because this was a single case and pregnancy safety data remain limited, it does not establish that ravulizumab is safe in pregnancy. Ravulizumab was also reported as successful in treating a COVID-19-triggered episode in a transplant recipient with a factor H mutation. In a separate transplant case, eculizumab was used around re-transplantation and the report described disease returning when eculizumab was withdrawn, which matched other signs of complement activation in that patient over time. [2] [3] [4]

What this means for patients and caregivers

For patients, this month mainly adds practical reassurance that complement blockers (eculizumab and ravulizumab) continue to be used in aHUS-related care across different ages and circumstances, with reports describing improvement and few safety problems noted. The strongest signals here come from the small pediatric series, while the pregnancy and transplant situations are each based on single-patient experiences, so they cannot predict what will happen for others. What remains uncertain is how to choose the best drug, how long to continue therapy, and which people can stop treatment without relapse, because these questions were not tested in larger comparative studies in this set of papers. This information may matter now as context for understanding what is being tried in routine care, and it may matter later if larger studies confirm which approaches are safest in specific situations like pregnancy and transplantation. [1] [2] [3] [4]

What this month showed

This month added a clearer biological explanation for how blood clots and kidney injury might be amplified in complement-mediated thrombotic microangiopathy: immune cell "webs" called NETs (neutrophil extracellular traps) were linked to more active disease and more complement-related injury in patient samples. In a mouse model and lab experiments, reducing NETs or the cells that make them led to less kidney injury and less complement attack on tissues. This does not prove a new treatment works in people yet, but it strengthens a specific chain of events that researchers can test in future human studies. [5]

In 107 patients, higher NET-related markers in blood and kidney tissue were reported alongside signs of more active disease and more membrane attack complex (a complement "pore" that can damage cells) in the kidney. The same report connected NETs to changes in CD59, a natural protective protein on kidney filters, including lower CD59 in the kidney and higher soluble CD59 in urine when NETs and complement injury were present. In plain language, this suggests that NETs may help strip away a protective layer and make complement-related damage easier to happen. [5]

In the mouse and lab parts of the same work, interventions that blocked NET formation or broke NETs apart (including PAD4-related approaches and DNase I) reduced kidney injury and reduced complement damage in the kidney, and removing neutrophils also reduced injury. Lab experiments suggested NETs could increase complement attack by causing CD59 shedding and could increase clotting signals by raising tissue factor in endothelial cells. Together, these experiments outline possible targets for future therapies, but they are still early and not tested as treatments in patients with aHUS. [5]

What this means for patients and caregivers

For patients, this set of findings mainly adds understanding of what might be driving tissue damage during active complement-mediated thrombotic microangiopathy, rather than changing care today. It introduces the idea that NETs and the loss of protective proteins like CD59 may be part of why complement injury becomes more intense, and it points to urine and tissue markers that could be explored for tracking disease activity in the future. What remains uncertain is whether measuring NET-related markers will help predict flares in everyday care, and whether NET-targeting approaches would be safe and effective in humans with aHUS. This matters most as a research direction that could eventually lead to new monitoring tools or add-on treatments if confirmed in clinical studies. [5]